Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy
Therapy results of 91 patients with newly diagnosed multiple myeloma who received autologous hematopoietic stem cells transplantation are presented. According to our data, survival depends on the preransplant response and the amount of transplantations. 5-years progressionfree survival in patients,...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849409167012397056 |
|---|---|
| author | Ye. I. Darskaya N. E. Marami-Zonuzi Yu. S. Osipov M. A. Estrina Ye. V. Babenko V. N. Vavilov B. V. Afanasiev |
| author_facet | Ye. I. Darskaya N. E. Marami-Zonuzi Yu. S. Osipov M. A. Estrina Ye. V. Babenko V. N. Vavilov B. V. Afanasiev |
| author_sort | Ye. I. Darskaya |
| collection | DOAJ |
| description | Therapy results of 91 patients with newly diagnosed multiple myeloma who received autologous hematopoietic stem cells transplantation are presented. According to our data, survival depends on the preransplant response and the amount of transplantations. 5-years progressionfree survival in patients, achieved pre-transplant complete or almost complete remission and received one auto-HSCT was 40 % compared with 18 % in patients who achieved only a partial response (p = 0.07). 10-years overall survival in patients received tandem auto-HSCT was40 % compared with 20 % in patients after one auto-HSCT. Statistically significant differences in 5-years progression-free survival (34 % after tandem auto-HSCT vs. 22 % after one auto-HSCT; p = 0.004) also were revealed. |
| format | Article |
| id | doaj-art-8eeceb13fd764601aa59d06771d332e5 |
| institution | Kabale University |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2014-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-8eeceb13fd764601aa59d06771d332e52025-08-20T03:35:34ZrusABV-pressОнкогематология1818-83462413-40232014-07-019161010.17650/1818-8346-2014-9-1-6-1020Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapyYe. I. Darskaya0N. E. Marami-Zonuzi1Yu. S. Osipov2M. A. Estrina3Ye. V. Babenko4V. N. Vavilov5B. V. Afanasiev6Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I.P. Pavlov First St.-Petersburg State Medical University, Ministry of Health of RussiaRaisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I.P. Pavlov First St.-Petersburg State Medical University, Ministry of Health of RussiaRaisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I.P. Pavlov First St.-Petersburg State Medical University, Ministry of Health of RussiaRaisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I.P. Pavlov First St.-Petersburg State Medical University, Ministry of Health of RussiaRaisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I.P. Pavlov First St.-Petersburg State Medical University, Ministry of Health of RussiaRaisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I.P. Pavlov First St.-Petersburg State Medical University, Ministry of Health of RussiaRaisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I.P. Pavlov First St.-Petersburg State Medical University, Ministry of Health of RussiaTherapy results of 91 patients with newly diagnosed multiple myeloma who received autologous hematopoietic stem cells transplantation are presented. According to our data, survival depends on the preransplant response and the amount of transplantations. 5-years progressionfree survival in patients, achieved pre-transplant complete or almost complete remission and received one auto-HSCT was 40 % compared with 18 % in patients who achieved only a partial response (p = 0.07). 10-years overall survival in patients received tandem auto-HSCT was40 % compared with 20 % in patients after one auto-HSCT. Statistically significant differences in 5-years progression-free survival (34 % after tandem auto-HSCT vs. 22 % after one auto-HSCT; p = 0.004) also were revealed.https://oncohematology.abvpress.ru/ongm/article/view/5multiple myelomaautologous hematopoietic stem cells transplantation |
| spellingShingle | Ye. I. Darskaya N. E. Marami-Zonuzi Yu. S. Osipov M. A. Estrina Ye. V. Babenko V. N. Vavilov B. V. Afanasiev Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy Онкогематология multiple myeloma autologous hematopoietic stem cells transplantation |
| title | Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy |
| title_full | Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy |
| title_fullStr | Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy |
| title_full_unstemmed | Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy |
| title_short | Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy |
| title_sort | therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy |
| topic | multiple myeloma autologous hematopoietic stem cells transplantation |
| url | https://oncohematology.abvpress.ru/ongm/article/view/5 |
| work_keys_str_mv | AT yeidarskaya therapyefficacyinmultiplemyelomapatientsreceivedautologousstemcellstransplantationasfirstlinetherapy AT nemaramizonuzi therapyefficacyinmultiplemyelomapatientsreceivedautologousstemcellstransplantationasfirstlinetherapy AT yusosipov therapyefficacyinmultiplemyelomapatientsreceivedautologousstemcellstransplantationasfirstlinetherapy AT maestrina therapyefficacyinmultiplemyelomapatientsreceivedautologousstemcellstransplantationasfirstlinetherapy AT yevbabenko therapyefficacyinmultiplemyelomapatientsreceivedautologousstemcellstransplantationasfirstlinetherapy AT vnvavilov therapyefficacyinmultiplemyelomapatientsreceivedautologousstemcellstransplantationasfirstlinetherapy AT bvafanasiev therapyefficacyinmultiplemyelomapatientsreceivedautologousstemcellstransplantationasfirstlinetherapy |